MASAHIRO OHKUBO

オオクボマサヒロ | MASAHIRO OHKUBO

Affiliation and department：
Job title： DEPUTY MANAGER

Research field (2)： Clinical pharmacy , Pharmaceuticals - chemistry and drug development

Research keywords (5)：特許 , ワクチン , 免疫 , Patent , Vaccine

Research theme for competitive and other funds (2)：

ワクチン、免疫、特許、知財
Vaccine Patent

MISC (18)：

OHKUBO Masahiro, HIRATA Takashi, SOGAME Yoshihisa, TANAKA Mikio, OKANO Kanemichi, TSUDA Yoshio. Metabolic Fate of a New Dihydropyridine Calcium Antagonist, AE0047. (III): Placental Transfer and Milk Transfer of 14C-AE0047. Drug Metabolism and Pharmacokinetics. 1997. 12. 3. 204-210
OHKUBO Masahiro, HIRATA Takashi, SOGAME Yoshihisa, TANAKA Mikio, OKANO Kanemichi, TSUDA Yoshio. Metabolic Fate of a New Dihydropyridine Calcium Antagonist, AE0047. (II): Lymphatic Absorption and Distribution of AE0047 in Rats. Drug Metabolism and Pharmacokinetics. 1997. 12. 3. 192-203
OHKUBO Masahiro, HIRATA Takashi, SOGAME Yoshihisa, TANAKA Mikio, OKANO Kanemichi, TSUDA Yoshio. Metabolic Fate of a New Dihydropyridine Calcium Antagonist, AE0047. (I): Absorption and Excretion of AE0047, in Rats and Dogs. Drug Metabolism and Pharmacokinetics. 1997. 12. 3. 178-191
KAMIGAKI T, YAMAMOTO M, OHYANAGI H, OHYA M, KONO A, OHTANI W, NARITA Y, OHKUBO M, SAITOH Y. Improved tumor defection by anti-CEA chimeric Fab oligomer with sisulfide linkages in a pancreatic? Carcinoma-xenograft model. Int.J.Cancer. 1996. 66. 2. 261-267
Improved tumor defection by anti-CEA chimeric Fab oligomer with sisulfide linkages in a pancreatic? Carcinoma-xenograft model. Int.J.Cancer. 1996. 66. 2. 261-267

ｍore...

Patents (3)：

かき肉中の低分子画分
血小板凝集抑制剤
血小板凝集抑制剤

Professional career (1)：

Doctor of Pharmacology (Kyoto Pharmaceutical University)

Association Membership(s) (6)：

日本水産学会 , 薬物動態学会 , 日本薬学会 , The Japanese Society of Fisheries Science , The Japanese Society for the study of Xenobiotics , The Pharmaceutical Society of Japan

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page